{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreig6bd5kj5qsn6ymkoededxnmcgapcmhunmvhmjqrpfbxlix6pymea",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mnuh57p4dnw2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiacjmde4ifw6xstczv2qxdbsgrkf4eg6iecvpnoz47fpjhhjqfyem"
    },
    "mimeType": "image/jpeg",
    "size": 243684
  },
  "path": "/news/2026-06-fda-xocova-covid-postexposure-prophylaxis.html",
  "publishedAt": "2026-06-09T09:40:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The U.S. Food and Drug Administration has approved Shionogi's Xocova (ensitrelvir), an oral antiviral, for postexposure prophylaxis (PEP) of COVID‑19 in adults and adolescents aged 12 years and older.",
  "title": "FDA approves Xocova for COVID-19 postexposure prophylaxis"
}